

# CONTROVERSIES & UPDATES

JANUARY 25-27 2018 C MARRIOTT RIVE GAUCHE & CONFERENCE CENTER PARIS, FRANCE WWW.CACVS.ORG


# **Does TEVAR affect the heart?**

#### Christos D. Liapis, MD, FACS, FRCS, FEBVS Professor (Em) of Vascular Surgery National & Kapodistrian University of Athens Director Vascular & Endovascular Clinic Athens Medical Center

#### NO DISCLOSURES RELATED TO THE TOPIC

## **Arterial Stiffness and cardiac outcomes**


Arterial stiffness has been correlated with long-term cardiovascular outcomes independent of traditional cardiovascular risk factors (e.g. hypertension, diabetes, obesity, dyslipidemia, smoking)



 Arterial stiffening results in increased pulse pressure, left ventricular hypertrophy, subendocardial ischemia, endothelial dysfunction and cardiac fibrosis

# Pulse wave velocity (PWV) and cardiac outcomes

Pulse wave velocity (PWV): the gold standard method of arterial stiffness measurement and a strong independent predictor of cardiovascular morbidity and mortality.




Therapeutic modalities reducing PWV are associated with less cardiovascular events rate and improved prognosis

# **Aortic Stiffness**


#### **OVERALL SURVIVAL**

American

Heart Association。



#### CARDIOVASCULAR SURVIVAL




Probabilities of overall survival (A) and event-free survival (cardiovascular mortality, B) in study population according to level of PWV divided into tertiles.


Blacher J. et al Circulation. 1999;99:2434-2439

## Changes in arterial stiffness in patients undergoing EVAR and TEVAR

#### Computational Fluid Dynamics Ongoing Trial









## Cardiovascular magnetic resonance elastography

Magnetic resonance elastography (MRE) is a phase-contrast magnetic resonance imaging technique that measures tissue stiffness non-invasively.



Khan S. et.al NMR in Biomedicine. 2017

### Arterial stiffness in patients with abdominal (AAA) or thoracic aortic aneurysms (TAA)



Men with AAA presented with significantly elevated PWV levels compared to agematched controls

- Mean blood pressure, AAA
   diameter and age: independent
   determinants of PWV in AAA
- TAA is associated with increased augmentation index

Shingu Y, et al Ann Thorac Surg 2009; Kadoglou NPE, Liapis C et al J Endovasc Surg 2012


#### Arterial stiffness, circulating vascular calcification inhibitors and inflammatory mediators in pts with AAA

|                          | AAA group<br>(N=108) | CO group (N=42)   | р       |
|--------------------------|----------------------|-------------------|---------|
| hsCRP (mg/L)             | $5.90 \pm 2.05$      | $2.96 \pm 1.02$   | < 0.001 |
| WBC (cells/µL)           | $9870 \pm 2231$      | $8850 \pm 2001$   | 0.039   |
| TC (mg/dl)               | $218 \pm 31$         | $184\pm48$        | 0.118   |
| HDL (mg/dl)              | $42 \pm 11$          | $45 \pm 13$       | 0.501   |
| LDL (mg/dl)              | $137 \pm 19$         | $113\pm22$        | 0.098   |
| TG                       | $148\pm56$           | $130\pm39$        | 0.319   |
| PWV (m/s)                | $12.99 \pm 3.75$     | $10.03\pm1.57$    | < 0.001 |
| Osteoprotegerin (pmol/L) | $16.11 \pm 3.01$     | $12.13 \pm 1.98$  | < 0.001 |
| Osteopontin (ng/ml)      | $54.4 \pm 16.05$     | $42.33 \pm 13.72$ | 0.047   |
| IL-6 (pg/ml)             | $5.51 \pm 2.42$      | $4.22 \pm 1.63$   | 0.038   |

|              | В     | р       |
|--------------|-------|---------|
| MBP          | 0.501 | < 0.001 |
| OPG          | 0.405 | 0.022   |
| OPN          | 0.204 | 0.272   |
| IL-6         | 0.251 | 0.189   |
| AAA diameter | 0.348 | 0.006   |

- PWV and hsCRP, WBC, IL-6, Osteoprotegerin were significantly upregulated in pts with AAA.
- Independent association of PWV with mean blood pressure, OPG and AAA diameter

### Changes in arterial stiffness in patients undergoing AAA repair



Stent-graft implantation (n=48) was associated with significant increase in PWV 6 months following EVAR


# Open surgical repair (n=39) of AAA induced modest increase of PWV and decreased by 8,5% the Augmentation index

- Kadoglou NP, Moulakakis KG, Liapis CD. Changes in aortic pulse wave velocity of patients undergoing endovascular repair of abdominal aortic aneurysms. J Endovasc Ther. 2012
- Lantelme P et al J Hypertens 2009

### **EVAR and cardiovascular Outcome**

- A non-significant tendency toward cardiovascular deaths was apparent in the EVAR trial in the endovascular group during the 24-month interval.
- Cardiovascular mortality was primarily due to the poor general health status of those patients or the required secondary interventions.
- A harmful effect of even slight alterations in aortic stiffness induced by endografts should be considered.
- 1. Brown LC, et al. EVAR trial participants. Incidence of cardiovascular events and death after open or endovascular repair of abdominal aortic aneurysm in the randomized EVAR trial 1. Br J Surg. 2011
- Brown LC, et al. EVAR trial participants. Does EVAR alter the rate of cardiovascular events in patients with AAA considered unfit for open repair? Results from the randomized EVAR trial 2. Eur J Vasc Endovasc Surg. 2010

### Short-term vs. long-term MI following EVAR and Open AAA Repair



Stather et.al British Journal of Surgery 2013; 100: 863-872

# **Cardiac effect of endovascular repair**


| Table 2. Baseline (Pre-Op) Characteristics of Patients and 7-Day (Post-Op) Outcomes After Endovascular           Aortic Repair |               |                |         |  |  |
|--|---------------|----------------|---------|--|--|
| Characteristic   | Pre-op (n=40) | Post-op (n=40) | P value |  |  |
| Systolic blood pressure (mmHg)   | 131±15        | 128±15         | 0.075   |  |  |
| Diastolic blood pressure (mmHg)  | 76±8          | 72±9           | <0.05   |  |  |
| Heart rate (beats/min)   | 65±10         | 69±12          | <0.05   |  |  |
| baPWV (cm/s)   | 1,914±389     | 2,096±459      | <0.05   |  |  |
| Inferior vena cava dimension (mm)  | 12±3          | 12±3           | 0.574   |  |  |
| LV volume index at end-diastole (ml/m <sup>2.7</sup> )   | 28.3±4.9      | 29.1±4.0       | 0.096   |  |  |
| Left atrial volume index (ml/m <sup>2.7</sup> )  | 13.7±4.4      | 15.4±4.6       | <0.05   |  |  |
| LVEF (%)   | 68±5          | 67±4           | 0.127   |  |  |
| IVST at end-diastole (mm)  | 9.0±2.3       | 9.1±2.3        | 0.623   |  |  |
| LV PWT at end-diastole (mm)  | 8.7±1.1       | 8.9±0.9        | 0.118   |  |  |
| LV PWT at end-systole (mm)   | 15.0±2.0      | 15.1±2.1       | 0.749   |  |  |
| DWS  | 0.41±0.09     | 0.40±0.09      | 0.429   |  |  |
| LV mass index (g/m <sup>2.7</sup> )  | 42±10         | 45±11          | <0.05   |  |  |
| Relative wall thickness  | 0.35±0.05     | 0.35±0.04      | 0.663   |  |  |
| E/A ratio  | 7.8±1.3       | 0.78±0.20      | 0.427   |  |  |
| Deceleration time of E wave (ms)   | 244±37        | 243±39         | 0.886   |  |  |
| E' (cm/s)  | 7.8±1.3       | 7.8±1.5        | 0.773   |  |  |
| E/E' ratio   | 8.2±1.8       | 8.4±1.5        | 0.385   |  |  |

Values are expressed as the mean  $\pm$  SD.

A, peak velocity of transmitral flow velocity curve at atrial contraction; baPWV, brachial-ankle pulse wave velocity; DWS, diastolic wall strain; E, peak early diastolic flow velocity of transmitral flow velocity curve; E', peak early diastolic velocity of the tissue Doppler imaging of the mitral annulus movement at septal position; EF, ejection fraction; IVST, interventricular septal thickness; LV, left ventricular; PWT, posterior wall thickness.

#### Takeda Y. et al Circ J 2014;78:322-328

## **Cardiac effect of endovascular repair**



Positive correlation between PWV and LV mass

Takeda Y. et al Circ J 2014;78:322-328

### **EVAR** alters cardiac structure and function


| Aortic Repair  |               |                  |         |
|--|---------------|------------------|---------|
| Characteristic   | Pre-op (n=22) | Follow-up (n=22) | P value |
| Specific activity scale score                          | 6.0±1.6       | 5.3±1.9          | <0.05   |
| Systolic blood pressure (mmHg)                         | 131±15        | 131±16           | 0.953   |
| Diastolic blood pressure (mmHg)                        | 75±8          | 74±10            | 0.476   |
| Heart rate (beats/min)                                 | 64±9          | 62±10            | 0.283   |
| baPWV (cm/s)   | 1,834±329     | 1,942±387        | <0.05   |
| Inferior vena cava dimension (mm)                      | 12±3          | 12±2             | 0.606   |
| LV volume index at end-diastole (ml/m <sup>2.7</sup> ) | 29.2±4.8      | 27.2±4.4         | <0.05   |
| Left atrial volume index (ml/m <sup>2.7</sup> )        | 14.0±5.3      | 16.2±4.7         | <0.05   |
| LVEF (%)   | 68±5          | 68±5             | 0.866   |
| IVST at end-diastole (mm)                              | 9.5±2.6       | 9.8±2.8          | 0.088   |
| LV PWT at end-diastole (mm)                            | 8.6±1.0       | 9.0±1.0          | 0.201   |
| LV PWT at end-systole (mm)                             | 15.0±1.7      | 14.8±2.4         | 0.646   |
| DWS  | 0.42±0.09     | 0.38±0.10        | 0.066   |
| LV mass index (g/m <sup>2.7</sup> )                    | 43±11         | 45±11            | <0.05   |
| Relative wall thickness                                | 0.35±0.05     | 0.37±0.04        | <0.05   |
| E/A ratio  | 0.82±0.21     | 0.75±0.19        | <0.05   |
| Deceleration time of E wave (ms)                       | 249±32        | 246±47           | 0.733   |
| E' (cm/s)  | 7.8±1.5       | 7.3±1.8          | 0.060   |
| E/E' ratio   | 8.5±1.7       | 8.6±2.1          | 0.052   |

Table 3. Baseline (Pre-Op) Characteristics of Patients and 1-Year (Follow-up) Outcomes After Endovascular

increased baPWV and induced left ventricular hypertrophy, left atrium enlargement and impaired diastolic function

Takeda Y et al Circ J 2014

## **Exercise tolerance**



Takeda Y. et al Circ J 2014;78:322-328

Changes in Arterial Stiffness and N-terminal pro-brain natriuretic peptide Levels after Endovascular Repair of Descending Thoracic Aorta


Twenty-seven patients with TAA underwent elective TEVAR. Blood samples were obtained preoperatively, 24 hr, 48 hr, and 6 months postoperatively.

Serum levels of NT-proBNP were measured. PWV was determined before and 6 months after TEVAR.

One-way analysis of variance by ranks was used to test the alterations in PWV (from baseline to 6 months) and NT-proBNP (along the 4 phases of evaluation). Post hoc analyses were appropriately performed.

# **Arterial stiffness and thoracic endografts**


M, 79y, Symptomatic 8cm TAA Medtronic VALIANT Thoracic 40X40, 46X46



# Endovascular repair



**Centre Hospitalier Régional** 









Proximal landing zone

**Courtesy of Rachel Clough** 

#### **PWV (m/sec) in baseline and 6 monts after TEVAR**




### NT-proBNP (pg/mL) among the different time points of evaluation after TEVAR



## Arterial stiffness and NT-proBNP changes following TEVAR


#### Kaplan – Meier survival curve estimate in follow up

| TEVAR Group, N=27, Baseline Characteristics            |                    |  |  |  |
|--|--------------------|--|--|--|
|  |                    |  |  |  |
|  |                    |  |  |  |
| Variable   | Mean ± SD or n (%) |  |  |  |
| Age (years)  | 68.8 ± 11.3        |  |  |  |
| Male Gender  | 24 (88.8)          |  |  |  |
| BMI (kg/m <sup>2</sup> )                               | 27.25 ± 4.6        |  |  |  |
| Indication for TEVAR                                   |                    |  |  |  |
| Atherosclerotic Aneurysm                               | 23 (85.2)          |  |  |  |
| Dissecting Aneurysm                                    | 2 (7.4)            |  |  |  |
| <ul> <li>Pseudoaneurysm</li> </ul>                     | 1 (3.7)            |  |  |  |
| Intramural Hematoma                                    | 1 (3.7)            |  |  |  |
| TAA Diameter (N=26) (cm)                               | 6.19 ± 1.3         |  |  |  |
| Chronic Obstructive Pulmonary Disease                  | 7 (25.9)           |  |  |  |
| Dyslipidemia   | 11 (40.7)          |  |  |  |
| CAD  | 9 (33.3)           |  |  |  |
| Diabetes Mellitus                                      | 6 (22.2)           |  |  |  |
| Smoking  | 15 (55.5)          |  |  |  |
| Hypertension   | 19 (70.3)          |  |  |  |
| History of Ascending Aorta Reconstruction              | 1 (3.7)            |  |  |  |
| History of AAA Reconstruction                          | 10 (37)            |  |  |  |
| Operative Characteristics                              |                    |  |  |  |
| <ul> <li>Aortic Pathology Length (cm)</li> </ul>       | 14.91±8.67         |  |  |  |
| <ul> <li>Subclavian Artery Coverage</li> </ul>         | 6 (22.2)           |  |  |  |
| Carotid - Subclavian Bypass                            | 2 (7.4)            |  |  |  |
| Celiac artery Coverage                                 | 6 (22.2)           |  |  |  |
| <ul> <li>Number of endografts placed: 1/2/3</li> </ul> | 13/11/3            |  |  |  |
| Duration of surgery (min)                              | $121.7 \pm 47.8$   |  |  |  |
| Blood loss (mL)  | $164.7 \pm 99.3$   |  |  |  |
| Follow-up 23.4 ± 16.4                                  |                    |  |  |  |
| 30-day Mortality 0                                     |                    |  |  |  |
| Mortality in Follow-up 9 (33.3)                        |                    |  |  |  |



Follow-up: 23.4 ± 16.4 months (range 3-54 months). Overall Mortality : 33.3%

### PWV and NT-proBNP changes in pts following TEVAR



Endovascular treatment of descending thoracic aortic aneurysms is associated with **significantly increased NT-proBNP levels and arterial stiffness**.

# <u>An increased cardiac risk for patients with already impaired cardiac compensatory mechanism ?</u>

# Differential effects of stent-graft fabrics on arterial stiffness in patients undergoing EVAR

| Structural Characteristics of the Stent-Grafts Used in the Study |         |   |   |  |
|--|---------|---|---|--|
| Device<br>Stent-Graft Structure                                  |         | Fabric and Skeleton                       | Fixation  |  |
| Anaconda   | Modular | Polyester and nitinol                     | Friction and hooks                                    |  |
| Excluder   | Modular | ePTFE and nitinol                         | Anchors   |  |
| Talent   | Modular | Polyester and nitinol                     | Suprarenal stent                                      |  |
| Endurant   | Modular | Polyester and nitinol                     | Suprarenal stent with anchor pins on the proximal end |  |
| Zenith FB  | Modular | Polyester and stainless steel and nitinol | Suprarenal bare stent with<br>anchoring barbs         |  |

|                                 | PTFE (n=46) | Polyester (n=72) | р     |
|---------------------------------|-------------|------------------|-------|
| Age, y                          | 70±9        | 71±7             | 0.568 |
| CAD                             | 14 (30.4%)  | 29 (40.3%)       | 0.382 |
| Diabetes                        | 8 (17.4%)   | 15 (20.8%)       | 0.793 |
| History of carotid surgery      | 3 (6.5%)    | 5 (6.9%)         | 0.482 |
| Smokers                         |             |                  |       |
| Baseline                        | 21 (45.6%)  | 24 (33.3%)       | 0.195 |
| End                             | 5 (10.9%)   | 6 (8.2%)         | 0.312 |
| Statins                         |             |                  |       |
| Baseline                        | 24 (52.2%)  | 44 (61.1%)       | 0.582 |
| End                             | 38 (82.6%)  | 66 (91.7%)       | 0.656 |
| Antihypertensive medications    |             |                  |       |
| Baseline                        | 39 (84.8%)  | 56 (77.8%)       | 0.711 |
| End                             | 42 (91.3%)  | 68 (94.4%)       | 0.819 |
| AAA diameter, cm                | 6.02±0.78   | 5.62±0.68        | 0.456 |
| Aortoiliac length, cm           | 14.9±1.7    | 15.1±1.9         | 0.812 |
| Endograft proximal diameter, cm | 2.65±0.24   | 2.69±0.33        | 0.944 |
| Endograft length, cm            | 13.75±1.63  | 13.67±1.75       | 0.912 |
| Type of endograft               | Excluder    | Anaconda (38)    |       |
| -                               |             | Zenith (28)      |       |
|                                 |             | Endurant (5)     |       |
|                                 |             | Talent (1)       |       |

# Prospective study

#### **N=118 pts**

Kadoglou NP, Moulakakis KG, Liapis CD. Differential effects of stentgraft fabrics on arterial stiffness in patients undergoing endovascular aneurysm repair. J Endovasc Ther. 2014

# Differential effects of stent-graft fabrics on arterial stiffness in patients undergoing EVAR

#### **N=118 pts**

#### Values of PWV and novel biomarkers at **baseline** and **after 12 months**

| Pulse Wave V               | elocity and Nov              |                            | Patients Underg<br>the Type of Ende | going Endovascula<br>ograft | ar Aneurys      | m Repair        |
|----------------------------|------------------------------|----------------------------|-------------------------------------|-----------------------------|-----------------|-----------------|
|                            | PTFE (n=46) Polyester (n=72) |                            | ter (n=72)                          |                             |                 |                 |
|                            | Baseline                     | End                        | Baseline                            | End                         | p1 <sup>†</sup> | p2 <sup>†</sup> |
| PWV, m/s<br>OPG, pmol/L    | 12.05±2.55<br>15.18±3.78     | 14.87±2.43*<br>10.51±4.46* | 12.63±2.75<br>15.72±5.02            | 16.75±2.88*<br>12.45±4.94*  | 0.685<br>0.803  | 0.033 0.048     |
| IL-8, pg/mL<br>IL-6, pg/mL | 11.27±5.09<br>3.81±1.51      | 17.97±8.1*<br>3.69±1.37    | 10.27±5.02<br>3.89±4.56             | 25.68±11.11*<br>3.58±1.50   | 0.681<br>0.944  | 0.001           |
| IL-10, pg/mL               | $5.35 \pm 1.57$              | 8.39±2.22*                 | 4.36±2.08                           | 7.64±1.52                   | 0.271           | 0.518           |

# PWV, OPG and IL-8 increase was more pronounced in Polyester Woven group compared to PTFE group (p=0.033, p=0.048, p<0.001 respectively)

Kadoglou NP, Moulakakis KG, Liapis CD. Differential effects of stent-graft fabrics on arterial stiffness in patients undergoing endovascular aneurysm repair. J Endovasc Ther. 2014

# **Conclusions (I)**

- TEVAR and EVAR are associated with lower perioperative mortality and morbidity rates compared to open surgical repair BUT this advantage is blunted at long term, mainly due to an increase in cardiovascular complications.
- Arterial stiffening together with adverse cardiac function after stent graft implantation may explain this change in the long-term outcome

# **Conclusions (II)**

- There is evidence of increased arterial stiffness after EVAR related to graft type (polyester more than PTFE). The effect of endograft type in the thoracic aorta is under investigation.
- Arterial stiffness should be taken into consideration by the industry when designing new endografts



# Thank you for your attention